La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Abbott Laboratories Crescita futura

Future criteri di controllo 2/6

Abbott Laboratories prevede che gli utili e i ricavi cresceranno rispettivamente di 11.8% e 6.5% all'anno. Si prevede che l'EPS crescerà di 11.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 21.5% in 3 anni.

Informazioni chiave

11.7%

Tasso di crescita degli utili

11.8%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.6%
Tasso di crescita dei ricavi	6.5%
Rendimento futuro del capitale proprio	21.5%
Copertura analitica	Good
Ultimo aggiornamento	23 Sep 2024

Aggiornamenti recenti sulla crescita futura

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Recent updates

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29

Previsioni di crescita degli utili e dei ricavi

NYSE:ABT - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	48,085	7,793	9,265	11,464	21
12/31/2025	44,774	6,813	8,978	10,723	24
12/31/2024	41,756	5,889	10,091	11,462	24
6/30/2024	40,725	5,535	5,654	7,900	N/A
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,153	4,492	6,549	N/A
6/30/2023	40,226	5,151	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	4,816	5,997	N/A
3/31/2018	28,445	365	N/A	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A
9/30/2013	20,275	961	N/A	3,202	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di ABT ( 11.8% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di ABT ( 11.8% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ABT cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di ABT ( 6.5% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ABT ( 6.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ABT sarà elevato tra 3 anni ( 21.5 %)

Abbott Laboratories Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Recent updates

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Chairman of the Board notifies of intention to sell stock

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Second quarter 2024 earnings: EPS misses analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

First quarter dividend of US$0.55 announced

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Insider notifies of intention to sell stock

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita